Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Sponsor
Chongqing Precision Biotech Co., Ltd
Study ID
NCT07318259
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BCMA/CD70 CAR-T cells — BIOLOGICAL
    Three dose groups (1.5×10\^5/kg, 5×10\^5/kg, 10×10\^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Study Details

This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Key Dates

First listed
Jan 5, 2026
Start date
Jan 26, 2026
Status verified
Dec 2025
Primary completion
Jul 31, 2026
Completion
Aug 31, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CAR-T treatment group
    This trial was designed as an open, single-arm, single-center, dose-increasing trial.

Primary Outcome Measure

The safety of CAR-T cell therapy in patients with refractory SLE [Safety] [ Time Frame: 3 months ]

Central Contacts

Find similar trials

Nationwide
Lupus (SLE) trialsRheumatology trialsAutoimmune disease trials

Related Studies